PR Newswire
24 Aug 2022, 06:30 GMT+10
GENEVA, Switzerland, Aug. 24, 2022 /PRNewswire/ -- The first US patient has been enrolled in the FDA SELUTION4BTK (Below-the-Knee) clinical trial evaluating SELUTION SLR, MedAlliance's novel sirolimus-eluting balloon. This milestone follows Investigational Device Exemption (IDE) approval in the US in May 2022, with enrollment of the first patient occurring in Germany one week after approval.
"We are very excited to finally have drug-eluting technology in the US to treat this difficult patient population," commented the trial's Principal Investigator (PI) Dr. Ehrin Armstrong. "We are encouraged by the positive early outcomes with this novel SELUTION SLR Sirolimus Drug Eluting Balloon (DEB) in Europe and Asia. We hope this FDA IDE trial will demonstrate significant benefit for patients who currently have limited treatment options."
The aim of the SELUTION4BTK clinical trial is to demonstrate the superior efficacy and equivalent safety of SELUTION SLR compared to plain (uncoated) balloon angioplasty (POBA) in the treatment of BTK arteries in Chronic Limb Threatening Ischemia (CLTI) patients. The trial is a prospective, multi-center, single blinded, randomized study (ClinicalTrials.gov Identifier: NCT05055297).
377 subjects are being randomized 1:1 to either SELUTION SLR or control treatment. This is the first study of its kind where 'real world' patients with CLTI can be included. Patients are being enrolled at approximately 40 sites across the US, Europe and Asia. This first US patient was enrolled at Vascular Solutions in Cary, North Carolina by Dr. Siddhartha Rao.
"We are very pleased to be participating in this groundbreaking study," said Dr Rao, "We hope that this promising technology will fulfill a huge need for our patients with chronic limb-threatening ischemia, saving life and limb. We look forward to the rapid enrolment of this trial."
"We were the first company to be granted 'Breakthrough Device Designation' for a DEB by the FDA and are proud to enrol the very first US patient in a sirolimus DEB study," added Jeffrey B. Jump, MedAlliance Chairman and CEO. "Many companies have been trying for years to bring sirolimus to the US and we are very pleased with our team for achieving this significant milestone. US patients will now have an alternative to paclitaxel DEB, addressing the concerns expressed by the FDA."
SELUTION SLR was awarded CE Mark Approval for the treatment of peripheral artery disease in February 2020 and for the treatment of coronary artery disease in May 2020. The US FDA has awarded SELUTION SLR with four breakthrough designations: for the treatment of atherosclerotic lesions in native coronary arteries; coronary in-stent restenosis; peripheral below-the-knee and AV-Fistula indications.
In August 2021, the first of over 3,000 patients was enrolled in a ground-breaking coronary randomized controlled study comparing SELUTION SLR with a limus drug-eluting stent (DES), powered to demonstrate superiority. SELUTION DeNovo is the largest DEB study ever initiated and has the potential to change medical practice.
MedAlliance's DEB technology involves unique MicroReservoirs made from biodegradable polymer intermixed with the anti-restenotic drug sirolimus. These MicroReservoirs provide controlled and sustained release of the drug for up to 90 days1. Extended release of sirolimus from stents has been proven highly efficacious in both coronary and peripheral vasculatures. MedAlliance's proprietary CAT (Cell Adherent Technology) enables the MicroReservoirs to be coated onto balloons and adhere to the vessel lumen when delivered via an angioplasty balloon.
SELUTION SLR is available in Europe and all other countries where the CE Mark is recognized.
About MedAlliance
MedAlliance is a privately-owned medical technology company. It is headquartered in Nyon, Switzerland, with offices in Germany, Singapore, UK and USA. MedAlliance specializes in the development of ground-breaking technology and commercialization of advanced drug device combination products for the treatment of coronary and peripheral artery disease. For further information visit: www.medalliance.com
1 Drug concentration evident in MicroReservoirs and tissue - Data on file at M.A. Med Alliance SA
Media Contact:
Richard Kenyon
[email protected]
+44 7831 569940
SOURCE MedAlliance
Get a daily dose of Malaysia Sun news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Malaysia Sun.
More InformationWASHINGTON, D.C.: Radio Free Asia, a key voice in press freedom across the continent for nearly three decades, is now warning it may...
HANOI, Vietnam: Brazil's largest meatpacker JBS is making a bold move into Southeast Asia, betting on Vietnam as a strategic hub for...
London [UK], April 7 (ANI): Following US President Donald Trump's reciprocal tariff move, UK Prime Minister Keir Starmer engaged in...
Washington DC [US], April 7 (ANI): Kevin Hassett, Director of the White House Economic Council, defended the impact of President Donald...
Mandalay [Myanmar], April 6 ( ANI): The Indian Army's Field Hospital, deployed in Mandalay as part of India's humanitarian assistance...
New Delhi [India] April 6 (ANI): India Cycling's foreign coach, Kevin Sireau, has highlighted the importance of regular sports participation...
Artificial intelligence (AI) has seen rapid growth, transforming industries and daily life. From chatbots to advanced generative models,...
WASHINGTON, D.C.: U.S. private sector hiring exceeded expectations in March, suggesting some underlying strength in the labor market...
BRUSSELS, Belgium: Major automakers, including Volkswagen, Stellantis, and Renault-Nissan, were hit with hefty fines this week after...
HONOLULU, Hawaii: Maui's mayor has proposed a plan to reduce vacation rentals to help with the housing shortage caused by the 2023...
WASHINGTON, D.C.: U.S. construction activity gained momentum in February, helped by falling mortgage rates that gave a boost to residential...
SINGAPORE: BOC Aviation is betting big on the future of air travel, placing major orders with both Airbus and Boeing as it moves to...